Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

Carly Helfand

So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker be the next company to keep it going.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS